Glenmark Pharmaceutical has launched its therapy for seasonal allergic rhinitis in the US. The nasal spray is the only-approved and fixed-dose combination treatment for seasonal rhinitis. With the help of Hikma Pharmaceuticals, a British drug giant, the Ryaltris nasal spray will be channelled in the US market. Unless Ryaltris is covered under insurance plans, according to the co-pay mechanism, patients will have to pay $49, said Glenmark’s CEO of Global Formulations Business.
Read More from Business Standard
English